Research programme: autoimmune disorder vaccines - Bristol Myers Squibb/Repertoire Immune Medicines
Alternative Names: Research programme: autoimmune disorders vaccines - Repertoire Immune Medicines/Bristol Myers SquibbLatest Information Update: 07 Aug 2024
At a glance
- Originator Repertoire Immune Medicines
- Developer Bristol-Myers Squibb; Repertoire Immune Medicines
- Class RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Multiple sclerosis; Type 1 diabetes mellitus; Unspecified
Most Recent Events
- 07 Aug 2024 Early research in Multiple sclerosis in USA (Parenteral), prior to August 2024 (Repertoire Immune Medicines pipeline, August 2024)
- 07 Aug 2024 Early research in Type 1 diabetes mellitus in USA (Parenteral), prior to August 2024 (Repertoire Immune Medicines pipeline, August 2024)
- 07 Aug 2024 Early research in Unspecified in USA (Parenteral), prior to August 2024 (Repertoire Immune Medicines pipeline, August 2024)